Introduction: Cancer associated thrombosis is a well-recognized phenomenon that results in considerable patient morbidity and mortality. Malignancy conveys an increased risk for thrombosis and chemotherapy further elevates this risk. The pathophysiological mechanisms underlying this process remain poorly defined. Materials and Methods: A human acute monocytic leukemia cell line (THP-1) was treated with commonly used anthracycline chemotherapeutics at concentrations similar to those found in the plasma of cancer patients. Cells were analyzed for tissue factor (TF) mRNA, protein, and activity. Microparticle (MP) TF activity was also measured. Phosphatidylserine (PS) exposure on cells and MPs was analyzed by flow cytometry. PS levels on MPs was also evaluated in an annexin V capture assay. Results: Anthracycline treatment of THP-1 cells resulted in a concentration-dependent increase in cellular TF activity without a change in TF protein, which was associated with increased PS exposure on the cell surface and apoptosis. The increase in TF activity was abolished by annexin V or lactadherin indicating that PS exposure was required. Anthracycline treatment of THP-1 cells also increased the number of TF-positive MPs. Conclusion: Treatment of THP-1 cells with anthracyclines induces apoptosis and increases cellular TF activity. The increased activity required an increase in exposure of PS. Additionally, anthracyclines increase the release of TF-positive MPs from THP-1 cells. We propose that the increase in cellular TF activity in circulating leukemic cells, combined with increased numbers of TF-positive MPs, may contribute to thrombosis in cancer patients receiving chemotherapy.

京都大学 / 0048 / 新制・課程博士 / 博士(工学) / 甲第21372号 / 工博第4531号 / 新制||工||1706(附属図書館) / 京都大学大学院工学研究科合成・生物化学専攻 / (主査)教授 梅田 眞郷, 教授 浜地 格, 教授 秋吉 一成 / 学位規則第4条第1項該当 / Doctor of Philosophy (Engineering) / Kyoto University / DGAM

No description available.

Les cellules eucaryotes possèdent un territoire membranaire dit « électrostatique » qui est définit par la présence de phospholipides négativement chargés sur la face cytosolique des membranes. Cette propriété permet le recrutement de protéine cytosolique contenant des motifs/domaines positivement chargés au niveau des membranes via des interactions électrostatiques. Nous nous sommes demandés si le territoire électrostatique est présent chez les cellules végétales et quel est son organisation ? Quels sont le(s) lipide(s) anionique(s) impliqués dans son maintien ? Et quel est son (ces) rôle(s) dans la signalisation et le développement des plantes ? Premièrement, nous avons mis en avant que la membrane plasmique est le compartiment intracellulaire le plus électronégativement chargé (Simon, Platre et al., 2016 Nature Plants). Ce champ électrostatique est gouverné par trois lipides anioniques différents, l’acide phosphatidique, la phosphatidylserine et le phosphatidylinositol-4-phosphate. Nous avons montré que cette propriété unique de la membrane plasmique permet de réguler des voies de signalisation hormonale, tel que celle de l’auxine et des brassinostéroïdes. Notamment, la phosphatidylserine régule la dynamique spatiotemporelle des petites GTPases de la famille Rho. En réponse à l’auxine, ce lipide permet de regrouper les protéines Rho dans des domaines membranaires. La formation de ces domaines est requise pour l’activité de ces protéines permettant de contrôler l’endocytose, la dynamique du cytosquelette mais également régule la morphogenèse cellulaire ainsi que la réponse gravitropique de la racine. / The « electrostatic territory» is part of the eukaryotic membrane organization and is defined by the enrichment of negatively charged phospholipids at the membrane cytosolic face. This feature is involved in the membrane recruitment of cytosolic proteins, which contain positively charged motifs and/or domains. In this work, we used Arabidopsis thaliana as a model and explored the existence of an electrostatic territory in plant cells. We found that the plasma membrane is the most anionic intracellular membrane (Simon, Platre et al., 2016 Nature Plants). This electrostatic field is maintained by lipid cooperation between, phosphatidic acid, phosphatidylserine and phosphatidylinositol-4-phosphate. The cell surface unique feature is involved in the regulation of hormonal signalling such as auxin and brassinosteroids pathways. We found that phosphatidylserine tunes the spatiotemporal dynamics of small GTPases from the Rho family. During auxin response, PS is required to cluster Rho into specialized membrane domains. We show that nanocluster formation is required for Rho-mediated auxin signaling including the regulation of endocytosis, cytoskeleton organization, morphogenesis and the root gravitropic response.

Lors d’une infection, les polynucléaires neutrophiles phagocytent l’agent pathogène et le détruisent grâce à la production de formes réactives de l’oxygène (FRO) par la NADPH oxydase. Cette enzyme est constituée de sous-unités membranaires (Nox2, p22phox) et cytosoliques (p67phox, p47phox,p40phox, Rac) qui s’assemblent soit à la membrane plasmique, lors de l’activation des cellules par un stimulus soluble comme le fMLF, soit à la membrane du phagosome, lors de la phagocytose de particules. La régulation de la NADPH oxydase implique divers facteurs comme la signalisation calcique et les lipides, notamment les phospholipides anioniques. En effet, il a été montré que l’activation et la translocation de la petite protéine G Rac peuvent être dépendantes du calcium. D’autre part les sous unités Rac et p47phox peuvent interagir avec les phospholipides anioniques tels que la phosphatidylsérine,grâce à des interactions stéréosélectives et/ou électrostatiques.L’objectif de ce travail est donc d’évaluer le rôle du calcium et de la phosphatidylsérine dans le recrutement de p47phox et/ou Rac lors de l’assemblage de NADPH oxydase. Pour suivre la dynamique des deux protéines, nous avons exprimé ces sous-unités marquées avec des protéines fluorescentes dans des lignées phagocytaires mimant les neutrophiles (HL-60 et PLB-985). Nous avons ainsi pu suivre, par vidéomicroscopie, le déplacement des sous-unités marquées lors d’une stimulation par fMLF ou PMA etdurant la phagocytose de particules opsonisées. Après stimulation par fMLF, Rac1 transloque du cytosol à la membrane plasmique, alors que le mutant constitutivement actif de Rac1 est constamment localisé àla membrane plasmique, indépendamment de la stimulation par fMLF. De plus après stimulation parPMA, le mutant constitutivement actif de Rac2 transloque à la membrane plasmique, suggérant que sa translocation pourrait être possible en absence d’un influx de calcium extracellulaire. Lors de la phagocytose, en masquant la phosphatidylsérine avec le domaine C2 discoïdine de la lactadhérine qui lie spécifiquement ce phospholipide, nous avons pu montrer que la phosphatidylsérine régule la production initiale des FRO en favorisant le recrutement de p47phox et de Rac2 au phagosome. De plus, ces deux sous-unités se détachent du phagosome alors que la production intraphagosomale de FRO continue,suggérant que leur départ n’est pas un signal de terminaison pour l’activité oxydase. Plus précisément,p47phox et Rac2 sont recrutées de manière transitoire, pendant seulement 1 à 3 minutes après la fermeture du phagosome. Ceci est en accord avec le modèle qui propose que p47phox servirait principalement à transporter p67phox au phagosome, et que les deux sous-unités p47phox et Rac2 faciliteraient le positionnement de p67phox dans le complexe membranaire. / During phagocytosis, neutrophils internalize pathogens in a phagosome and kill them through the production of reactive oxygen species (ROS) by the NADPH oxidase enzyme. The cytosolic NADPHoxidase subunits (p67phox p47phox, p40phox, Rac2) and the membranous subunits (Nox2, p22phox) assemble either at the plasma membrane after stimulation with soluble agonist, or at the phagosomal membrane during particle phagocytosis. The regulation of this enzyme involves several actors like calciumsignalling and anionic phospholipids. Actually Rac activation and translocation was found to be calciumdependent and, on the other hand, p47phox and Rac can interact with anionic phospholipids such asphosphatidylserine through stereoselective and/or electrostatic interactions.Therefore we wanted to investigate the role of calcium and phosphatidylserine in p47phox and Rac membrane recruitment. To study this dynamic, we expressed the subunits tagged with a fluorescent protein in neutrophil-like cells (HL-60 and PLB-985), and followed them by videomicroscopy duringfMLF or PMA stimulation or during phagocytosis of opsonised particles. After fMLF stimulation, Rac1translocated from the cytosol to the plasma membrane whereas constitutively active form of Rac1 was permanently located at the plasma membrane, independently of fMLF stimulation. In addition, afterPMA treatment, constitutively active form of Rac2 translocated to the plasma membrane, suggesting that its translocation could occur without extracellular calcium entry. By using the specific phosphatidylserine binding discoïdine C2 domain of lactadherin, we could mask this phospholipid and found that phosphatidylserine is involved in NADPH oxidase activity by participating in the phagosomal recruitment of p47phox and Rac2. In addition we show that these two subunits detached from the phagosome while ROS production continued for a longer period, suggesting that their dissociation from the complex is not a termination signal for oxidase activity. More precisely, p47phox and Rac2 were briefly recruited to the phagosomal membrane, for 1 to 3 minutes after the phagosome closure. These results support the model in which p47phox serves as a carrier for p67phox and both p47phox and Rac2 are adapters that correctly position p67phox in the complex.

Ebola viruses, and other members of the family filoviridae, are enveloped, negative sense, RNA viruses that can cause hemorrhagic fever. Currently, there are no antivirals or approved vaccines available that target or protect from Ebola virus infection. However, recently, T-cell immunoglobulin and mucin domain-1 (TIM-1) has been identified as an epithelial-cell receptor for filoviruses and could be a potential target for antivirals. However, little is known about how TIM-1 enhances virus entry and the role of TIM-1 during in vivo infection. In order to determine the key residues of TM-1 involved in interaction with virus, we generated a panel of point-mutations in the immunoglobulin-like variable (IgV) domain of TIM-1. We determined that several residues within the IgV domain that are involved in binding of phosphatidylserine (PtdSer) are also critical for Ebola virus entry. Further, we found that TIM-1 interacts with Ebola virus through binding of PtdSer on the viral envelope. PtdSer liposomes, but not phosphatidylcholine liposomes, competed with TIM-1 for EBOV pseudovirion binding and transduction. In addition, annexin V (AnxV) substituted for the TIM-1 IgV domain, supporting a PtdSer-dependent mechanism. Our findings suggest that TIM-1-dependent uptake of EBOV occurs by apoptotic mimicry. We also determined that TIM-1 expression can enhance infection of a wide range of enveloped viruses, including alphaviruses and a baculovirus. As further evidence of the critical role of enveloped virion associated PtdSer in TIM-1-mediated uptake, TIM-1 enhanced internalization of pseudovirions and virus-like particles (VLPs) lacking a glycoprotein, providing evidence that TIM-1 and PtdSer-binding receptors can mediate virus uptake independent of a glycoprotein. These results provide evidence for a broad role of TIM-1 as a PtdSer-binding receptor that mediates enveloped virus uptake. The PtdSer-binding activity of the IgV domain is essential for both virus binding and internalization by TIM-1. However, another member of the TIM family, TIM-3, whose IgV domain also binds PtdSer, does not effectively enhance virus entry. These data indicate that other domains of TIM proteins are functionally important. We investigated the domains of the TIM family members that play a role in the enhancement of enveloped virus entry, thereby defining the features necessary for a functional PVEER. Using a variety of chimeras and deletion mutants, we found that in addition to a functional PtdSer binding domain PVEERs require a stalk domain of sufficient length, containing sequences that promote an extended structure. Neither the cytoplasmic nor the transmembrane domain of TIM-1 is essential for enhancing virus entry, provided the protein is still plasma membrane bound. Based on these defined characteristics, we generated a mimic lacking TIM sequences and composed of annexin V, the mucin-like domain of α-dystroglycan, and a glycophosphatidylinositol anchor that functioned as a PVEER to enhance transduction of virions displaying Ebola, Chikungunya, Ross River, or Sindbis virus glycoproteins. This identification of the key features necessary for PtdSer-mediated enhancement of virus entry provides a basis for more effective recognition of unknown PVEERs. Provided that expression of TIM-1 in cells enhances virus entry through binding of PtdSer on the viral membrane, we wanted to determine whether virus entry would still be enhanced if this interaction was reversed with TIM-1 present on the viral membrane. Further, we reasoned that this might allow for targeting of virus to cells with greater amounts of PtdSer exposed on their outer leaflet, such as cancer cells. In order to test this hypothesis, we generated virions in cells coexpressing a glycoprotein and one of the TIM family members. We found that expression of TIMs in virus-producing cells resulted in TIM proteins being released into the virus-containing medium and enhanced Ebola virus GP pseudovirion titers. Further, this enhancement was dependent on the amount of PtdSer exposed on the target-cell membrane. However, we also determined that TIMs were not being incorporated into virions and that coexpression of TIMs with non-ebolavirus glycoproteins in virus-producing cells resulted in virus stocks with both reduced titers and the quantity of virions.

Platelet-derived microparticles, released as a result of platelet activation, promote coagulation through the surface exposure of phosphatidylserine, acting as the catalytic site for the conversion of prothrombin to thrombin by the activated coagulation factors X and V. Although elevated numbers of circulating platelet-derived microparticles can be detected in a number of clinical disorders, the methods for the detection of these microparticles are far from standardised. In addition, recent reports have also speculated that not all microparticles may expose phosphatidylserine, demonstrating that the binding of Annexin V, a phosphatidylserine-specific binding protein, is not detectable on a population of microparticles. The initial stage of this thesis was to establish a flow cytometric method for the detection and enumeration of microparticles based on their capacity to bind Annexin V and to utilise this assay to investigate a number of the issues that have limited assay standardisation. The assay could be performed on either stimulated or unstimulated plasma or whole blood samples. Interestingly, plasma microparticle counts were significantly higher than whole blood microparticle counts. The effects of centrifugation alone could not be attributed as the sole source of this discrepancy. The antigenic characteristics of platelet-derived microparticles were also investigated, with platelet-derived microparticles demonstrated to express the platelet glycoproteins CD31, CD41a, CD42a and CD61. Platelet-derived microparticles also expressed CD42b, and this expression was significantly decreased when compared to their progenitor platelets. The expression of the platelet activation markers CD62p, CD63, CD40L and PAC-1 was dependent upon the sample milieu, suggesting that the centrifugation conditions required to generate platelet-poor plasma may lead to artefactual increases in the expression of platelet activation markers. An investigation of the role of the GpIIb/IIIa complex on the formation of platelet-derived microparticles was also performed. A monoclonal antibody to the GpIIb/IIIa complex (Abciximab) significantly inhibited in vitro collagen-stimulated platelet-derived microparticle formation. Interestingly, platelets obtained from two subjects with impaired GpIIb/IIIa activation, demonstrated normal microparticle formation following collagen stimulation, suggesting that the presence of GpIIb/IIIa complex, but not its activation, is required for collagen-induced microparticle formation. A novel mechanism for microparticle formation was also investigated, with platelet-derived microparticles demonstrated to form in response to the sclerosing agents sodium-tetradecyl sulphate and polidocanol. Interestingly, the removal of plasma proteins by the washing of platelets left platelets more susceptible to sclerosant-induced microparticle formation, suggesting that plasma proteins may protect platelets from microparticle formation. The procoagulant activity of platelet-derived microparticles was also investigated using a novel coagulation assay (XACT) specific for the procoagulant phospholipid. An evaluation of this assay demonstrated a significant correlation between Annexin V binding microparticle counts and procoagulant activity in both whole blood and plasma samples. There was more procoagulant activity in whole blood samples than in plasma samples, suggesting that the procoagulant phospholipid activity was also associated with erythrocytes or leukocytes. To further investigate this phenomenon, a whole blood flow cytometric assay was developed to assess Annexin V binding to erythrocytes, leukocytes, platelets and microparticles. This assay demonstrated that a large proportion of Annexin V binding (51.0%) was associated with erythrocytes. Interestingly, a proportion of the Annexin V binding erythrocytes (24.5%) and leukocytes (78.8%) were also associated with platelet CD61 antigen, suggesting that they also bound a platelet or platelet-derived microparticle. The effect of sample anticoagulant on microparticle procoagulant activity was investigated. Microparticle counts were most stable in EDTA anticoagulated samples, but were stable in sodium citrate for up to 15 minutes following sample collection. The procoagulant activity of microparticles was significantly inhibited by EDTA in collagen-stimulated platelet-rich plasma samples, when compared to sodium citrate anticoagulated samples. Although the initial method used to investigate microparticles was based upon their ability to bind Annexin V, it was consistently observed that a large proportion of events in the size region of a microparticle were Annexin V negative. An investigation was therefore commenced into the procoagulant activity of microparticles based on their capacity to bind Annexin V. The presence of Annexin V negative microparticles was confirmed by flow cytometry and the proportion of microparticles that bound Annexin V was dependent upon type of agonist used to stimulate microparticle formation. Varying the assay constituents (calcium concentration / Annexin V concentration / buffer type) did not alter the proportion of Annexin V binding microparticles. When compared to Annexin V positive microparticles, Annexin V negative microparticles expressed significantly higher levels of CD42b on their surface, but possessed significantly decreased expressions of CD62p, and CD63. A significant correlation between the percentage of Annexin V binding and XACT procoagulant activity was found (p=0.03). Furthermore, Annexin V binding inhibited greater than 98% of procoagulant phospholipid activity, suggesting that Annexin V binding was a true reflection of procoagulant activity. Microparticles could be sorted using either a flow cytometric or magnetic sorting strategy. By electron microscopy, Annexin V negative events isolated following magnetic sorting were vesicular structures and not small platelets or the remnants of activated platelets. In summary, this thesis has demonstrated the ability of the flow cytometer and XACT assays to detect microparticles and their procoagulant activity. It has also shown that the use of Annexin V to detect microparticles may warrant further investigation.

No description available.

Platelet-derived microparticles, released as a result of platelet activation, promote coagulation through the surface exposure of phosphatidylserine, acting as the catalytic site for the conversion of prothrombin to thrombin by the activated coagulation factors X and V. Although elevated numbers of circulating platelet-derived microparticles can be detected in a number of clinical disorders, the methods for the detection of these microparticles are far from standardised. In addition, recent reports have also speculated that not all microparticles may expose phosphatidylserine, demonstrating that the binding of Annexin V, a phosphatidylserine-specific binding protein, is not detectable on a population of microparticles. The initial stage of this thesis was to establish a flow cytometric method for the detection and enumeration of microparticles based on their capacity to bind Annexin V and to utilise this assay to investigate a number of the issues that have limited assay standardisation. The assay could be performed on either stimulated or unstimulated plasma or whole blood samples. Interestingly, plasma microparticle counts were significantly higher than whole blood microparticle counts. The effects of centrifugation alone could not be attributed as the sole source of this discrepancy. The antigenic characteristics of platelet-derived microparticles were also investigated, with platelet-derived microparticles demonstrated to express the platelet glycoproteins CD31, CD41a, CD42a and CD61. Platelet-derived microparticles also expressed CD42b, and this expression was significantly decreased when compared to their progenitor platelets. The expression of the platelet activation markers CD62p, CD63, CD40L and PAC-1 was dependent upon the sample milieu, suggesting that the centrifugation conditions required to generate platelet-poor plasma may lead to artefactual increases in the expression of platelet activation markers. An investigation of the role of the GpIIb/IIIa complex on the formation of platelet-derived microparticles was also performed. A monoclonal antibody to the GpIIb/IIIa complex (Abciximab) significantly inhibited in vitro collagen-stimulated platelet-derived microparticle formation. Interestingly, platelets obtained from two subjects with impaired GpIIb/IIIa activation, demonstrated normal microparticle formation following collagen stimulation, suggesting that the presence of GpIIb/IIIa complex, but not its activation, is required for collagen-induced microparticle formation. A novel mechanism for microparticle formation was also investigated, with platelet-derived microparticles demonstrated to form in response to the sclerosing agents sodium-tetradecyl sulphate and polidocanol. Interestingly, the removal of plasma proteins by the washing of platelets left platelets more susceptible to sclerosant-induced microparticle formation, suggesting that plasma proteins may protect platelets from microparticle formation. The procoagulant activity of platelet-derived microparticles was also investigated using a novel coagulation assay (XACT) specific for the procoagulant phospholipid. An evaluation of this assay demonstrated a significant correlation between Annexin V binding microparticle counts and procoagulant activity in both whole blood and plasma samples. There was more procoagulant activity in whole blood samples than in plasma samples, suggesting that the procoagulant phospholipid activity was also associated with erythrocytes or leukocytes. To further investigate this phenomenon, a whole blood flow cytometric assay was developed to assess Annexin V binding to erythrocytes, leukocytes, platelets and microparticles. This assay demonstrated that a large proportion of Annexin V binding (51.0%) was associated with erythrocytes. Interestingly, a proportion of the Annexin V binding erythrocytes (24.5%) and leukocytes (78.8%) were also associated with platelet CD61 antigen, suggesting that they also bound a platelet or platelet-derived microparticle. The effect of sample anticoagulant on microparticle procoagulant activity was investigated. Microparticle counts were most stable in EDTA anticoagulated samples, but were stable in sodium citrate for up to 15 minutes following sample collection. The procoagulant activity of microparticles was significantly inhibited by EDTA in collagen-stimulated platelet-rich plasma samples, when compared to sodium citrate anticoagulated samples. Although the initial method used to investigate microparticles was based upon their ability to bind Annexin V, it was consistently observed that a large proportion of events in the size region of a microparticle were Annexin V negative. An investigation was therefore commenced into the procoagulant activity of microparticles based on their capacity to bind Annexin V. The presence of Annexin V negative microparticles was confirmed by flow cytometry and the proportion of microparticles that bound Annexin V was dependent upon type of agonist used to stimulate microparticle formation. Varying the assay constituents (calcium concentration / Annexin V concentration / buffer type) did not alter the proportion of Annexin V binding microparticles. When compared to Annexin V positive microparticles, Annexin V negative microparticles expressed significantly higher levels of CD42b on their surface, but possessed significantly decreased expressions of CD62p, and CD63. A significant correlation between the percentage of Annexin V binding and XACT procoagulant activity was found (p=0.03). Furthermore, Annexin V binding inhibited greater than 98% of procoagulant phospholipid activity, suggesting that Annexin V binding was a true reflection of procoagulant activity. Microparticles could be sorted using either a flow cytometric or magnetic sorting strategy. By electron microscopy, Annexin V negative events isolated following magnetic sorting were vesicular structures and not small platelets or the remnants of activated platelets. In summary, this thesis has demonstrated the ability of the flow cytometer and XACT assays to detect microparticles and their procoagulant activity. It has also shown that the use of Annexin V to detect microparticles may warrant further investigation.

The p53 protein is a primary mediator of apoptosis and growth arrest after exposure to DNA-damaging agents. Previous work has categorised a wild type p53 gene in the majority of childhood acute lymphoblastic leukaemia (ALL) cases, in which instance the p53 protein functions as a modulator of chemotherapy-induced cell death. In contrast, certain p53-induced proteins, such as p21WAF1, can act in an anti-apoptotic manner, and bestow resistance to chemotherapy. Previous studies of the p53 pathway in ALL have utilised cell lines and primary material. In this study a model of ALL was utilised that had previously been developed from a heterogeneous panel of patient biopsies established as xenografts in immune-deficient mice, and are adaptable for short term in vitro culture. A wild-type p53 protein response to etoposide and nutlin-3 exposure was a feature of the whole ALL xenograft panel, irrespective of clinical characteristics and disease biology. While a range of p53 target genes were induced in B-cell precursor (BCP)-ALL and T-ALL xenografts after etoposide exposure, there was negligible induction of p21WAF1 in T- ALL samples. Further work with the histone deacetylase inhibitor vorinostat facilitated p53-independent induction of p21WAF1 in BCP-ALL samples, yet failed to induce p21WAF1 in T- ALL. An association was observed between reduced p21WAF1 expression in the T-ALL samples and decreased histone H3 acetylation in the p21WAF1 promoter together with increased cytosine methylation in the first exon/intron of the p21WAF1 gene. These results suggest that p21WAF1 in T-ALL cells is subject to epigenetic modifications that cause transcriptional silencing. Defective induction of p21WAF1 in T-ALL xenografts was associated with increased sensitivity to the death-inducing effects of drugs, phosphatidylserine (PS) externalisation and caspase-3/-7 activity after drug exposure, indicating that p21WAF1 may exert an anti-apoptotic activity. As proof of principle, p21WAF1 was silenced in Nalm-6 cells by micro-RNA transduction and these cells exhibited increased sensitivity and rapid PS externalisation after drug exposure. A combination of a p21WAF1 inhibitory agent and vorinostat gave some pharmacological evidence to suggest that p21WAF1 inhibition could enhance drug efficacy. Overall, these investigations provide insight into the epigenetic regulation of p21WAF1 and demonstrate an anti-apoptotic role for p21WAF1 in childhood ALL cells.